Most drug interactions are mediated by various cytochrome P450 enzymes. CYP1A2 inhibitors Since<unk>  is metabolised through the CYP1A2 enzyme pathway, any drug which inhibits this enzyme is likely to precipitate the toxicity of<unk> : concomitant therapy is to be avoided. Fluvoxamine is contraindicated in patients who are on treatment with<unk> . Other inhibitors of CYP1A2 such as ciprofloxacin, amiodarone and propafenone should be used with caution. Other CYP inhibitors Some<unk>  is also metabolized by cytochrome P450 enzymes other than CYP1A2. Consequently, strong inhibitors of other cytochrome P450 enzymes such as fluconazole (CYP2C9), chloramphenicol (CYP2C19), fluoxetine and paroxetine (both CYP2D6) should be used with caution. CYP1A2 inducers Moderate inducers of CYP1A2 such as omeprazole should be used with caution since they might reduce the circulating plasma levels of the drug. Cigarette smoking Cigarette smoking causes increased clearance of<unk>  by inducing CYP1A2, thereby decreasing exposure to the drug. Patients must be advised to abstain from cigarette smoking while on therapy with<unk> .
Pirfenidone
Lurasidone
Chlortalidone
Methylphenidate
Dexmethylphenidate
Rimonabant
Ethylphenidate
Pirlindole